SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is currently drawing significant attention as investors shift toward defensive, high-quality dividend compounders amid broader market volatility. The community is actively debating whether the stock's current price levels represent a strategic accumulation point for long-term wealth building or a potential value trap as the company navigates ongoing cost-savings initiatives.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active call buying as the community debates potential short-squeeze dynamics and the impact of a high short interest against an anticipated operational turnaround. Traders are closely monitoring the stock's price action around critical technical levels, fueled by speculation regarding activist interest and upcoming earnings, while opinions remain sharply divided on the company's long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul><p>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.</p><p>“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.</p><p>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;</p><p>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.</p><h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2><p>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;</p><p>Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;</p><p>The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;</p><h2 class="st-heading-2">Retail reaction</h2><p>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;</p><p>Shares in the company have fallen around 10% so far this year.&nbsp;</p>

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

Equity

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 


<ul class="summary-bullets"><li>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.</li><li>Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.</li><li>ADMA stock has declined nearly 29% since Culper’s short report was released on Tuesday.</li></ul><p>Adma Biologics Inc. (ADMA) has been downgraded by analysts at Cantor Fitzgerald, with the firm citing disappointment among investors following the company’s response to a short report.</p><p>According to TheFly, Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">short report</a> on Tuesday.</p><p>Cantor downgraded Adma Biologics to ‘Neutral’ from ‘Overweight’ without a price target. ADMA stock has declined nearly 29% since Culper’s short report was released.</p><p><a href="https://stocktwits.com/symbol/ADMA">Adma Biologics’ shares</a> were down more than 2% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.</p><h2 class="st-heading-2">What Is Cantor Concerned About?</h2><p>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.</p><p>Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.</p><p>According to Koyfin, the average 12-month price target for ADMA stock is $23.5, implying a return potential of 144% from current levels. Of the three analyst ratings, two have a ‘Buy’ recommendation, while one has a ‘Hold’ rating.</p><h2 class="st-heading-2">What Did The Short Report Flag?</h2><p>Culper Research stated in its short report that Adma Biologics’ sales growth is driven by a “de facto channel stuffing scheme.” The firm stated that Adma’s revenue declined 3% in 2025, after adjusting for sales inflation, while the company reported a 20% growth.</p><p>The short seller also noted that the sales of Adma’s flagship product, Asceniv, have been inflated by 40% to 76%. “We believe the ASCENIV growth story is total fiction owing entirely to channel stuffing,” Culper added.</p><p>The firm added that, based on its interactions with two high-level employees at one of Adma’s largest distributors, the biopharmaceutical company induced the distributor to stock excess Asceniv by offering rebates and extended payment terms to meet the distributor's order expectations.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>One user on the platform stated that even if a part of Culper’s short report is true, it gives the company a black eye.</p><p><stembedurl>https://stocktwits.com/Tradeswithyourmom/message/648578343</stembedurl></p><p>However, a bullish user dismissed the short report, saying that there is nothing to see here.</p><p><stembedurl>https://stocktwits.com/glacier64/message/648588280</stembedurl></p><p><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> is down 47% year-to-date and 52% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 17% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 42%.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-us-ceasefire-plan-maximalist-unreasonable-white-house-weekend-talks/cZ3YvQ5RISH"><strong>Iran Reportedly Says US Ceasefire Proposal Is 'Extremely Maximalist And Unreasonable' Even As White House Plans Weekend Talks</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence

Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its short report on Tuesday.

<ul class="summary-bullets"><li>Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising."</li><li>The firm now awaits additional data in the second half of 2026 to better assess Sarepta's programs.</li></ul><p>Shares of Sarepta Therapeutics (SRPT) closed 35% higher on Wednesday despite Wall Street raising concerns on the company’s early clinical results for two of its programs in neuromuscular diseases.</p><p>Leerink analyst Joseph Schwartz said the initial data released by the company earlier on Wednesday in genetic diseases myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy type 1 (FSHD1) are "a bit of a mixed bag." While it seems like they can achieve "impressive" muscle concentration, the DM1 data are "very limited and safety remains an open debate," said the analyst, who has a ‘Market Perform’ rating on Sarepta shares.</p><p>Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." However, the early nature of data and use of different sample sizes across measurements may bias the results, preventing conclusion, the analyst told investors in a research note. The firm awaits additional data in the second half of 2026 to better assess Sarepta's programs. The firm has an ‘Outperform’ rating on Sarepta with a $37 price target.</p><h2 class="st-heading-2">Sarepta’s Trial Data</h2><p>Sarepta said earlier in the day that early results from the studies of its investigational siRNA treatment SRP-1001 in FSHD1 and DM1 demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerability, which the company expects will lead to better clinical efficacy.</p><p>Both DM1 and FSDH1 are genetic disorders caused by overexpression of mutant proteins or toxic mRNA and characterized by progressive muscle weakness. The experimental treatment is designed to reduce, or knock down, the production of DUX4 protein in skeletal muscle.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has dropped 68% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP">Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."

<ul class="summary-bullets"><li>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity.</li><li>It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes.</li><li>DigitalOcean is the Agentic Inference Cloud built for AI-native and Digital-native enterprises scaling production workloads.</li></ul><p>DigitalOcean (DOCN) shares plunged nearly 9% during extended hours of trading on Tuesday after it announced that it has commenced an underwritten public offering of $700 million of its shares.&nbsp;</p><p>Additionally, DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.</p><p>The company in a statement said that the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p><h2 class="st-heading-2">Purpose To Use Proceeds</h2><p>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity, beyond what it has previously communicated, to support customer demand for DigitalOcean’s cloud&nbsp;or AI platform.&nbsp;</p><p>It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes. DigitalOcean is in advanced discussions to secure this additional data center capacity to support its growth, it said.&nbsp;</p><h2 class="st-heading-2">What Is DigitalOcean</h2><p>DigitalOcean is the agentic inference cloud built for AI-native and digital-native enterprises scaling production workloads. The platform combines production-ready GPU infrastructure with a full-stack cloud to deliver operational simplicity and predictable economics at scale. The company has more than 640,000 customers.</p><h2 class="st-heading-2">Retail Reaction</h2><p>Retail sentiment around DOCN trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company have jumped 75% year-to-date.&nbsp;</p><p>&nbsp;</p>

Shares of DigitalOcean have jumped 75% year-to-date. 

Why Is DigitalOcean Plunging Today?

DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul><p>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.</p><p>Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.</p><p>The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.</p><h2 class="st-heading-2">Analyst Takeaway</h2><p>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.</p><p>The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.</p><h2 class="st-heading-2">About Vyondys And Amondys</h2><p>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.</p><p>While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.</p><p>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.</p><h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2><p>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Vanguard or iShares: Which Offers the Better Small-Cap ETF?

Key PointsVanguard Small-Cap ETF charges half the expense ratio of iShares Core S&P Small-Cap ETF, but both are extremely low-cost...

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul><p>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.</p><h2 class="st-heading-2">Gene Therapy Study Details</h2><p>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</p><p>Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.</p><p>Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.</p><p>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">Street Consensus</h2><p>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

Small-Cap ETFs: SCHA Owns the Whole Neighborhood, IJR Checks the Financials First

Key PointsSchwab U.S. Small-Cap ETF charges a lower expense ratio, but iShares Core S&P Small-Cap ETF pays a slightly higher dividend yield...

<ul class="summary-bullets"><li>It is possible that the talks might not culminate in a deal, the report added.</li><li>Fertitta’s bid reportedly tops a rival offer from investor Carl Icahn’s firm for Caesars.</li><li>Icahn’s offer has not been officially rejected by Caesars.</li></ul><p>Shares of Caesars Entertainment (CZR) rose 12% on Wednesday following a report that billionaire Tilman Fertitta has been in talks to buy the gaming company for $7 billion.</p><p>The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/tilman-fertitta-in-talks-to-buy-caesars-for-7-billion-after-topping-bid-from-icahn-119907e0">reported</a>, citing people familiar with the matter, that Fertitta's company behind the Golden Nugget casino chain, Fertitta Entertainment, has been discussing paying around $34 a share for Caesars. The offer price represents a premium of about 31% from the stock’s closing price on Tuesday.</p><p>It is possible that the talks might not culminate in a deal, the report added.</p><h2 class="st-heading-2">Competing Bids</h2><p>Fertitta’s bid reportedly tops a rival offer from investor Carl Icahn’s firm for Caesars. Icahn Enterprises (IEP) had made an all-cash offer of about $33 per share for Caesars, the report said, while adding that Icahn’s offer has not been officially rejected by Caesars.</p><p>Late last month, the Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/caesars-entertainment-stock-closes-up-19-percent-on-takeover-buzz/cZTGp5zRIRX">reported</a> that Caesars is also considering a possible management-led buyout. Shares of the company closed up 19% on the day.</p><p>Eldorado Resorts completed its acquisition of Caesars Entertainment Corporation in 2020 for approximately $17.3 billion, creating the largest U.S. casino operator. The merged entity rebranded as Caesars Entertainment.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CZR shares rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘extremely low’ to ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/CZR">CZR stock</a> has risen 4% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syk-stock-slips-on-report-of-global-outage-spurred-by-suspected-iran-linked-cyberattack/cZdr4HWRIJx">SYK Stock Slips On Report Of Global Outage Spurred By Suspected Iran-Linked Cyberattack</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Caesars Entertainment logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CZR Stock Climbs On Report Of Buyout Talks With Billionaire Tilman Fertitta

The Wall Street Journal reported, citing people familiar with the matter, that Fertitta's company Fertitta Entertainment has been discussing paying around $34 a share for Caesars.

<ul class="summary-bullets"><li>Papa John’s is now reviewing the bid but there is no guarantee that the bid will result in an agreement, the report said.</li><li>For Irth, it is its second attempt at acquiring Papa Johns after it made an attempt last year alongside private-equity firm Apollo Global Management, sources told the Journal.&nbsp;</li><li>For fiscal year 2025, Papa John’s reported adjusted and diluted earnings per common share of $1.43, down from $2.34 in the prior year as it battles rising competition.</li></ul><p>Shares of Papa John's (PZZA) rose over 18% on Wednesday following a report that the company has received a take-over bid valuing the business at about $1.5 billion.</p><p>The Wall Street Journal reported, citing people familiar with the matter, that the Qatari-backed investment fund Irth Capital Management has submitted a bid to take the pizza chain private.</p><p>As per the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/papa-johns-draws-fresh-takeover-interest-85f6490a">report</a>, Irth offered to pay $47 per share. This represents a 44% premium from the stock’s closing price on Tuesday.</p><p>Papa John’s is now reviewing the bid but there is no guarantee that the bid will result in an agreement, the report said, while also highlighting the possibility of another suitor emerging.</p><h2 class="st-heading-2">Second Attempt</h2><p>For Irth, it is its second attempt at acquiring Papa Johns after it made a bid last year alongside private-equity firm Apollo Global Management, sources told the Journal.</p><p>Irth is an existing shareholder in Papa Johns and has increased its effective stake to about 10%, the report added. A deal for Papa Johns would be one of Irth’s first major moves, the report noted.</p><h2 class="st-heading-2">Papa John’s FY25</h2><p>For fiscal year 2025, Papa John’s reported total revenue of $2.1 billion, flat compared to the prior year, and adjusted diluted earnings per common share of $1.43, down from $2.34 in the prior year as it battles rising competition.</p><p>In February, the company committed to sharpening its marketing message in light of the competitive dynamics in its business. The company also said it will close underperforming restaurants.</p><p>“Optimizing our restaurant portfolio and strategically closing underperforming restaurants are among the most impactful actions we can take to improve restaurant profitability and fleet health,” CFO Ravi Thanawala then said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PZZA stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/PZZA">PZZA stock</a> has fallen by about 17% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-rallies-on-significant-debt-reduction-retail-cheers-insider-confidence/cZdrPzQRIJM">VELO Stock Rallies More Than 20% On Significant Debt Reduction — Retail Cheers Insider Confidence</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

American pizza restaurant franchise, Papa John's Pizza, logo seen in Spain. (Photo by Xavi Lopez/SOPA Images/LightRocket via Getty Images)

PZZA Stock Soars More Than 18% On Report Of Take-Private Bid At $1.5B Valuation

The Wall Street Journal reported, citing people familiar with the matter, that the Qatari-backed investment fund Irth Capital Management has submitted a bid to take Papa John's private.

iShares Trust - iShares Core S&P Small-Cap ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$125.43
Prev Close	$124.92
Open	$123.12
Dividend Yield	N/A
50-Day Moving Average	$127.21
Beta	N/A
Avg. Volume	8.06M
PE Ratio	N/A

52-Week High	$133.52
52-Week Low	$89.22
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IJR
iShares Core S&P Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IJR News

IJRiShares Core S&P Small-Cap ETF